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Summary
Background The Clinicopathological and Gene Expression Profile (CP-GEP) model
was developed to accurately identify patients with T1–T3 primary cutaneous mel-
anoma at low risk for nodal metastasis.
Objectives To validate the CP-GEP model in an independent Dutch cohort of
patients with melanoma.
Methods Patients (aged ≥ 18 years) with primary cutaneous melanoma who
underwent sentinel lymph node biopsy (SLNB) between 2007 and 2017 at the
Erasmus Medical Centre Cancer Institute were eligible. The CP-GEP model combi-
nes clinicopathological features (age and Breslow thickness) with the expression
of eight target genes involved in melanoma metastasis (ITGB3, PLAT, SERPINE2,
GDF15, TGFBR1, LOXL4, CXCL8 and MLANA). Using the pathology result of SLNB
as the gold standard, performance measures of the CP-GEP model were calcu-
lated, resulting in CP-GEP high risk or low risk for nodal metastasis.
Results In total, 210 patients were included in the study. Most patients presented
with T2 (n = 94, 45%) or T3 (n = 70, 33%) melanoma. Of all patients, 27%
(n = 56) had a positive SLNB, with nodal metastasis in 0%, 30%, 54% and 16%
of patients with T1, T2, T3 and T4 melanoma, respectively. Overall, the CP-GEP
model had a negative predictive value (NPV) of 905% [95% confidence interval
(CI) 779–96.2], with an NPV of 100% (95% CI 722–100) in T1, 893% (95%
CI 728–963) in T2 and 750% (95% CI 301–954) in T3 melanomas. The CP-
GEP indicated high risk in all T4 melanomas.
Conclusions The CP-GEP model is a noninvasive and validated tool that accurately
identified patients with primary cutaneous melanoma at low risk for nodal metas-
tasis. In this validation cohort, the CP-GEP model has shown the potential to
reduce SLNB procedures in patients with melanoma.
What is already known about this topic?
• The majority (70–85%) of patients with cutaneous melanoma who undergo a sen-
tinel lymph node biopsy (SLNB) procedure have no metastasis in the SLN.
• To identify patients at low risk for nodal metastasis, the Clinicopathological and
Gene Expression Profile (CP-GEP) model was developed (n = 754 patients, US
cohort).
• The CP-GEP model combines age, Breslow thickness and the expression of eight
target genes involved in melanoma metastasis, and has the potential to reduce SLNB
procedures in patients with T1–T3 cutaneous melanoma.
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What does this study add?
• This is the first independent validation of the CP-GEP model in European patients
with primary cutaneous melanoma.
• The CP-GEP model can be applied to full-excision tumour tissue and does not
require macrodissection of tumour tissue.
• The CP-GEP model has a negative predictive value of 905% (95% confidence
interval 779–962) in T1–T3 melanomas.
• The CP-GEP model is a promising tool in patient care. In this validation cohort,
the CP-GEP model has shown the potential to reduce SLNB procedures in patients
with primary cutaneous melanoma.
The incidence rates of cutaneous melanoma are high and
range from 15 per 100 000 person-years in the European
population, 48 per 100 000 person-years in the USA, and up
to 72 per 100 000 person-years for Australian inhabitants.1–3
The prognosis for patients with melanoma mainly depends on
the ability of melanoma cells to migrate from the primary
region into the regional lymph nodes (stage III) and/or
organs (stage IV).4–6 Traditionally, sentinel lymph node
biopsy (SLNB) is used for accurate disease staging and prog-
nostic stratification.7–11 With the introduction of adjuvant sys-
temic therapy in patients with surgically resected high-risk
stage III melanoma (i.e. IIIA with nodal metastasis > 1 mm,
IIIB and IIIC), recurrence-free survival rates improved signifi-
cantly.12–14 Subsequently, SLNB has become an important tool
to outline treatment planning as well.15
According to current national and international melanoma
guidelines,16–18 patients with ≥ T1b cutaneous melanoma,
who represent about half of all patients with cutaneous mela-
noma, are eligible for SLNB to determine SLN status.9,19 The
most recent estimates of the number of SLNB procedures per-
formed in the adjuvant therapy era are not yet available. How-
ever, before the introduction of adjuvant therapy, only 40–
63% of eligible patients in Europe underwent SLNB.20–24 This
could be attributed to the fact that, although less invasive than
elective lymph node dissection, morbidity associated with
SLNB is not negligible.22,25 In addition, the SLNB positivity
rate varies between 15% and 30%.8,26–28 Thus, for the major-
ity of patients, SLNB will not lead to therapeutic conse-
quences, but will be merely informative. Moreover, patients
without an indication for SLNB can still present with metas-
tases in the regional lymph node basin.
Considering the above, a more accurate identification of
SLNB candidates is required, especially for lower T stages.
Recently, Bellomo et al. described the discovery of a Clinico-
pathological and Gene Expression Profile (CP-GEP) model.29
This model combines age and Breslow thickness with gene
expression of eight target genes in the primary melanoma.
These eight target genes are involved in melanoma metastasis
and include ITGB3, PLAT, SERPINE2, GDF15, TGFBR1, LOXL4,
CXCL8 and MLANA. The CP-GEP model was developed in
patients with T1–T3 primary cutaneous melanoma in the USA,
and can identify patients with a very low risk (< 5%) of nodal
metastasis, with a negative predictive value (NPV) > 95%.29
In line with current clinical guidelines,16,18 the CP-GEP
model was developed for a high NPV, with a low false-negative
rate.29 In the USA, the prevalence (and, consequently, the pre-
test probability) of nodal metastases in patients with melanoma
is lower (15–20%) compared with Europe (up to 30%).8,26–28
As NPV is inversely related to the prevalence of nodal metasta-
sis, the NPV of CP-GEP is expected to be lower in a European
cohort. Therefore, the primary aim of the current study was to
clinically validate the CP-GEP model in an independent Dutch
cohort. A validated CP-GEP model can help to accurately iden-
tify patients with primary cutaneous melanoma and a low risk
for nodal metastasis, thereby potentially reducing the rate of
negative SLNB procedures. As macrodissection prior to RNA
isolation is time consuming, the secondary aim of this study is
to validate the CP-GEP model on tumour tissue obtained by full
excision instead of macrodissection. This will facilitate imple-
mentation in daily clinical practice.
Materials and methods
Study population
The study included patients aged 18 years or older who were
diagnosed with primary cutaneous melanoma and underwent
SLNB at the Erasmus Medical Centre (MC) Cancer Institute,
between 2007 and 2017. Patients who underwent SLNB more
than 90 days after the primary melanoma diagnosis were
excluded as well as patients with multiple primary melanomas,
or missing data on Breslow thickness or age (at the time of
primary diagnosis).
The study was approved by the Erasmus MC Ethics Commit-
tee (MEC-2018-1183) and the Privacy Committee of the
Nationwide Network and Registry of Histopathology and
Cytopathology (PALGA). Human residual tissue was used
according to the code of conduct for responsible use of the
Federation of Dutch Medical Scientific Societies. None of the
patients objected to the use of their residual tissue for scien-
tific research. The study was reported according to the TRI-
POD statement.30
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Retrieval and processing of formalin-fixed paraffin-
embedded primary melanoma
In order to retrieve the pathology conclusion of the primary
melanoma all eligible patients were linked to PALGA.31 The
availability of pathology reports on the corresponding SLN,
reporting on the main SLNB outcome (i.e. presence or absence
of metastasis), was required. All SLN slides were re-evaluated
to determine the combined Rotterdam tumour load and
Dewar topography criteria.32 The first surgical procedure on
the primary melanoma was selected for retrieval of the forma-
lin-fixed paraffin-embedded (FFPE) tumour specimen (i.e.
diagnostic biopsy or diagnostic excision). Pathology laborato-
ries were asked to send the FFPE tumour blocks to the Eras-
mus MC Cancer Institute. The pathologist assessed the
presence of sufficient material and revised the original pathol-
ogy report by using a haematoxylin and eosin stained slide. In
the case of discrepant reports, the evaluation of the pathologist
of the Erasmus MC Cancer Institute was used. To prevent RNA
contamination a new knife was used to section each patient’s
FFPE sample. Five standard-thickness (10 micron) recuts were
collected in a single standard 15-mL microcentrifuge tube,
and stored refrigerated until RNA isolation.
Processing of the formalin-fixed paraffin-embedded
primary melanoma
For molecular analysis of tumour tissue, macrodissection is
often implemented to reduce background noise of the sur-
rounding tissue. The CP-GEP model was developed using
mainly shave and punch biopsies. Therefore, the need for
macrodissection of full-excision slides prior to RNA isolation
for CP-GEP was also assessed. A more detailed description is
provided in Methods S1 (see Supporting Information).
Quantitative polymerase chain reaction and the
Clinicopathological and Gene Expression Profile model
RNA extraction and quantitative polymerase chain reaction
(qPCR) of target genes (ITGB3, PLAT, SERPINE2, GDF15, TGFBR1,
LOXL4, CXCL8 and MLANA) and two housekeeping genes (RLP0
and b-actin) is described in detail in Methods S1 (see Support-
ing Information). To calculate the CP-GEP probability score,
differences obtained in cycle threshold (DCt) values were
combined with clinicopathological factors (Breslow thickness
and age, both included as linear related continuous variables)
as input for the logistic regression model. For each patient,
the CP-GEP score was compared with the predefined cut-off
value of a predicted probability of 0063, resulting in a pre-
dicted low risk or high risk for nodal metastasis.29
Statistical analyses
A sample size calculation was not performed as all eligible
patients in the Erasmus MC were included. Using the SLNB
pathology result as the gold standard, the accuracy of the CP-
GEP model was calculated. In the analysis, SLNs with minimal
tumour burden according to the combined Rotterdam tumour
load and Dewar topography criteria (≤ 04 mm subcapsular
and/or ≤ 01 mm any location) were considered as positive
lymph nodes.32 For this validation study, the regression coeffi-
cients and threshold from the development cohort were
used.29 Gene expression measurements in the development
cohort had been conducted via Chip-Based qPCR (Fluidigm
platform), while gene expression for the validation cohort was
conducted using conventional qPCR (QuantstudioDx plat-
form). Prior to performing this validation, a bridging study
was performed to assess the impact of this change in qPCR
platform on gene expression values. During the bridging
study, samples from the development cohort were rerun on
the QuantstudioDx platform. After comparing CP-GEP out-
comes on both platforms, only the threshold had to be
adjusted to use the QuantstudioDx platform for the gene
expression measurements.
The performance of the CP-GEP model was characterized by
calculating sensitivity, specificity, NPV, positive predictive
value (PPV) and corresponding 95% confidence interval (CI).
These performance measures were stratified on T stage accord-
ing to the 8th edition of the American Joint Committee on
Cancer (AJCC) staging system.6 To measure the model dis-
crimination between patients with and without SLN metasta-
sis, the area under the receiver operating curve (ROC) was
calculated. To describe the model calibration (i.e. agreement
between observed and predicted outcomes), a calibration
curve was constructed. Perfect predictions should be on the
45° line, described by an intercept (a) of 0 and a slope (b)
of 1. Statistical analyses were performed with SPSS version
240 (IBM, Armonk, NY, USA) and R version 36.1 (2019-
07-05) using the PredictABEL and rms package, with a P-
value < 005 (two-sided) indicating statistical significance.
Results
Study population
Between January 2007 and December 2017, 333 patients with
primary cutaneous melanoma underwent SLNB, 297 of whom
were included in the study. Of those, 85 patients were
excluded as no adequate data or (sufficient) FFPE samples
could be retrieved, resulting in qPCR analysis of 212 samples.
Two samples did not fulfil the quality control of the qPCR
analysis and were excluded from the analysis as well, resulting
in a final study population of 210 patients. An overview of
the sample selection is provided in Figure 1. Descriptive statis-
tics are provided in Table 1. The study population consisted
of slightly more male (52%) than female patients and the
median age was 55 years [interquartile range (IQR) 45–65] at
diagnosis of the primary melanoma. Median Breslow thickness
was 205 mm (IQR 140–330 mm). Most patients presented
with a T2 (n = 94, 45%) or T3 (n = 70, 33%) melanoma.
Overall, 56 (27%) of the patients had a positive SLNB, of
whom 17 (30%), 30 (54%) and nine (16%) patients
© 2020 The Authors. British Journal of Dermatology
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presented with T2, T3 and T4 melanoma, respectively. Differ-
ences in input values between this study population and the
original development cohort are presented in Table S1 (see
Supporting Information).
Processing of the formalin-fixed paraffin-embedded
primary melanoma
To test the need for macrodissection of tumour tissue before
RNA isolation, 20 FFPE melanoma samples were used
(Table S2 and Figure S1; see Supporting Information). For
each sample, full-excision and macrodissected histological
slides were utilized to extract RNA and subsequently conduct
qPCR analysis. Macrodissection resulted in a reduction of the
RNA yield compared with the full-excision histological slides
for the same sample. One full-excision and four macrodis-
sected samples provided an RNA yield below the recom-
mended 500 ng. However, using a lower input amount of
RNA did not affect the results of the CP-GEP model (note a in
Table S2; see Supporting Information). The results of the CP-
GEP model and binary outcomes were highly concordant
between full-excision and macrodissected histological slides
for the same sample. Based on these results, macrodissection
was not performed during the remainder of the study, and
only full-excision slides were included in the performance
analyses of the CP-GEP model.
Performance of the Clinicopathological Gene Expression
Profile model
According to the CP-GEP model, 42 of 210 patients (20%)
were classified as low risk for nodal metastasis, whereas 168
patients (80%) were classified as high risk (Table 2). When
these results were compared with the known histopathological
SLN status (positive/negative), the CP-GEP model correctly
classified 38 melanomas as low risk; only four samples were
misclassified as low risk, while the SLN was positive. The
model discrimination, as measured by the area under the ROC
was 066 (95% CI 059–074) for T1–T4. The calibration plot
is shown in Figure S2 (see Supporting Information). The cor-
responding intercept (a) is –0428 and calibration slope (b)
is 0346, indicating that predicted probabilities were systemat-
ically too low and too extreme. However, as the predicted
probabilities were dichotomized at a predefined probability of
0063, both the sensitivity and the NPV remained high. The
CP-GEP model had a sensitivity of 915% (95% CI 801–
966), a specificity of 297% (95% CI 225–381), a PPV of
323% (95% CI 250–407), and an NPV of 905% (95% CI
779–962) (T1–T3). In one of the four misclassified SLNs,
the micrometastatic tumour burden was low. In total, the
cohort included seven patients with low metastatic tumour
burden in the SLN, of which six were identified by the CP-
GEP model as being high risk.




Samples excluded (n = 1): 
• No pathology data in PALGA, n = 1
Pathology report primary melanoma 
n = 297
Samples excluded (n = 35): 
• SLNB after second primary melanoma, n = 15
• Primary melanoma > 90 days before SLNB, n = 12
• Incomplete pathology report of the primary melanoma, n = 8
FFPE primary melanoma retrieved
n = 212
Samples excluded (n = 85): 
• No FFPE primary melanoma retrieved:
• Patient < 18 years, n = 2
• No permission from patient to use FFPE melanoma, n = 0
• No opt-out permission possibility to use FFPE melanoma, n = 1
• FFPE primary melanoma not present in archives, n = 12
• Insufficient FFPE primary melanoma, n = 26
• Incorrect FFPE primary melanoma, n = 1
• No response from pathology lab, n = 43
Samples excluded (n = 2): 
• Insufficient quality of qPCR analysis, n = 2
Final analyses
n = 210
Figure 1 Flowchart of the sample selection procedure. SLNB, sentinel lymph node biopsy; MC, Medical Centre; PALGA, nationwide network and
registry of histopathology and cytopathology; FFPE, formalin-fixed paraffin-embedded; qPCR, quantitative polymerase chain reaction.
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Discussion
In an independent European cohort of patients with primary
cutaneous melanoma, the CP-GEP model was validated to
accurately identify patients at low risk for nodal metastasis.
Overall NPV of the CP-GEP model was 905% (95% CI 779–
962). RNA isolation from full-excision histological slides
resulted in the same CP-GEP probability scores and outcome




n = 56 (27)
SLNB negative,
n = 154 (73)
CP-GEP high risk,
n = 168 (80)
CP-GEP low risk,
n = 42 (20)
Sex, male 110 (52) 31 (55) 79 (52) 85 (51) 25 (60)
Age, years 55 (45–65) 53 (45–64) 56 (45–67) 54 (44–65) 61 (49–68)
Breslow thickness, mm 205 (140–330) 270 (185–380) 190 (130–310) 230 (170–380) 115 (110–140)
Ulceration
Present 55 (26) 21 (38) 34 (22) 53 (32) 2 (5)
Absent 149 (71) 34 (61) 115 (75) 110 (65) 39 (93)
Unknown 6 (3) 1 (2) 5 (3) 5 (3) 1 (2)
T stage, AJCC 8th edition
T1 11 (5) 0 11 (7) 1 (1) 10 (24)
T1a 5 (2) 0 5 (3) 1 (1) 4 (10)
T1b 6 (3) 0 6 (4) 0 6 (14)
T2 94 (45) 17 (30) 77 (50) 66 (39) 28 (67)
T2a 79 (38) 15 (27) 64 (42) 53 (32) 26 (62)
T2b 13 (6) 2 (4) 11 (7) 11 (7) 2 (5)
T2a or T2b 2 (1) 0 2 (1) 2 (1) 0
T3 70 (33) 30 (54) 40 (26) 66 (39) 4 (10)
T3a 42 (20) 15 (27) 27 (18) 38 (23) 4 (10)
T3b 24 (11) 14 (25) 10 (6) 24 (14) 0
T3a or T3b 4 (2) 1 (2) 3 (2) 4 (2) 0
T4 35 (17) 9 (16) 26 (17) 35 (21) 0
T4a 18 (9) 4 (7) 14 (9) 18 (11) 0
T4b 17 (8) 5 (9) 12 (8) 17 (10) 0
Tumour location
Arm 33 (16) 7 (13) 26 (17) 28 (17) 5 (12)
Head/neck 1 (1) 0 1 (1) 1 (1) 0
Leg 66 (31) 17 (30) 49 (32) 51 (30) 15 (36)
Trunk 110 (52) 32 (57) 78 (51) 88 (52) 22 (52)
Minimal tumour burden in the SLN 7 (3) 7 (13) N/A 6 (4) 1 (2)
AJCC, American Joint Committee on Cancer; SLN(B), sentinel lymph node (biopsy); CP-GEP, Clinicopathological Gene Expression Profile.











CP-GEP high risk 133 1 66 66 35
True positive 43 0 14 29 9
False positive 90 1 52 37 26
CP-GEP low risk 42 10 28 4 0
True negative 38 10 25 3 0
False negative 4 0 3 1 0
Sensitivity 915% 0 824% 967% 100%
95% CI (801–966) (590–938) (833–994) (701–100)
Specificity 297% 909% 325% 75% 0
95% CI (225–381) (623–984) (231–435) (26–199)
PPV 323% 0 212% 439% 257%
95% CI (250–407) (131–325) (326–559) (142–421)
NPV 905% 100% 893% 750% 0
95% CI (779–962) (722–100) (728–963) (301–954)
CP-GEP, Clinicopathological Gene Expression Profile; CI, confidence interval; NPV, negative predictive value; PPV, positive predictive value.
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compared with RNA isolation from macrodissected slides, ren-
dering macrodissection of the tumour tissue unnecessary.
Until recently, SLN status could be used only as a diagnostic
and prognostic tool in patients with primary cutaneous mela-
noma.8,9,28,33 Since the introduction of adjuvant systemic
therapy, SLNB is performed to identify candidates for these
treatment strategies.12–14 Therefore, it is expected that the
number of patients with melanoma who undergo SLNB will
increase. Validation of the CP-GEP model in an independent
European cohort with SLNB was required, as the population
of patients with melanoma with SLNB is significantly different
in the USA. In the development cohort, the prevalence of
nodal metastasis was 17%,29 whereas our validation cohort
had a prevalence of 27%. This lower pre-test probability of
nodal metastasis in the USA23,24,34–37 can be attributed to
more defensive diagnostics in the USA23,38,39 and differences
in histopathological SLN examination between the USA and
Europe.40 Furthermore, patients with minimal tumour burden
in the SLN were excluded from the main analysis in the US
development cohort, as both pathological evaluation of the
SLN and patient prognosis can be considered to be ambigu-
ous.32 However, we did not exclude them from our validation
study, as inclusion of these patients reflects current clinical
practice. Thus, we included these seven patients in the analy-
ses as having nodal metastases, of whom six were classified as
high risk by the CP-GEP model. The CP-GEP model outper-
formed all models based on clinical and pathological variables
in the development cohort (area under the ROC 082). The
performance of the CP-GEP model in our European cohort as
measured by model discrimination (area under the ROC) and
calibration (intercept and calibration slope) seemed low, but
the original threshold still resulted in a high sensitivity
(915%) and a high NPV (905%). Although the number of
false positives is high, the NPV is the most important outcome
measure, as the CP-GEP model has been developed as a dese-
lection tool. Also, a high sensitivity was maintained, indicating
that almost no SLN metastasis would have been missed.
For thick melanomas (T4), most clinicians will recommend
SLNB, irrespective of the CP-GEP result.16,18 For this reason,
T4 melanomas were not included in the development cohort.
In the current validation cohort, 35 patients with T4 melano-
mas were included, but, as was expected, none of these mela-
nomas was classified as low risk by CP-GEP. The use of the
CP-GEP prediction model to select patients for SLNB will be
most relevant for lower T stages, as SLNB is controversial in
these patients. As clinical guidelines do not recommend SLNB
when the risk for nodal metastasis is < 5%,18 the test has been
developed to have a very high NPV (> 95%), resulting in a
low negativity rate.29 Consequently, patients with a false-posi-
tive CP-GEP test (51% of patients with T1–T3 melanomas in
this validation cohort) will be referred for SLNB. However, in
current clinical practice, the number of patients with a nega-
tive SLN is even higher (up to 85%).8,26–28 Although the NPV
is inversely related to the prevalence of nodal metastasis, the
NPV was high and consistent across both cohorts, i.e. 96%
(development cohort) and 905% (validation cohort).29 This
validation study showed that the CP-GEP model may reduce
the number of SLN-negative procedures in patients with T2
and T3 melanomas at low risk for nodal metastasis. Ongoing
validation studies, which include more T1 melanomas (with
and without nodal metastasis), will provide more accurate
reduction rates for T1. Recently, the CP-GEP assay has also
been discussed for its use in pandemic times, such as coron-
avirus disease 2019 (COVID-19).
Most GEPs have been developed to predict prognosis rather
than SLNB outcome. Recently, a 31-GEP has been repurposed
to predict SLNB outcome in patients with primary cutaneous
melanoma.41 However, the utility of 31-GEP has been focused
on patients 65 years or older, for whom it has been proven to
be cost-effective.42 Besides, the 31-GEP requires macrodissec-
tion of melanoma tissue, which is time consuming. The current
CP-GEP model has not been designed for patients of a certain
age, and does not require macrodissection of the melanoma tis-
sue. In addition to the full-excision histological slides, which
can be performed with standard pathology laboratory equip-
ment, only two clinicopathological variables (age and Breslow
thickness) are needed to calculate the probability score.
In terms of strengths and limitations, by using a nationwide
pathology database (i.e. PALGA), the pathology data of almost
all patients could be retrieved, thereby completing AJCC stag-
ing data and preventing both selection and information bias.
In addition, PALGA also enabled the collection of FFPE pri-
mary melanoma tissue from any medical centre in the Nether-
lands. This was of the utmost importance, because SLNB is
usually performed in melanoma centres, i.e. the Erasmus MC
Cancer Institute, whereas primary melanoma is usually diag-
nosed in local centres.
The low number of T1 melanomas (n = 11, 5% of the vali-
dation cohort) and lack of nodal metastasis in this group could
be interpreted as a limitation of the study, but is rather a result
of adequate deselection (based on current clinical guidelines)
for SLNB of these patients. However, 10 (out of 11) patients
with a T1 melanoma could have safely forgone SLNB and one
patient would have undergone SLNB without having SLN
metastasis, if the CP-GEP model outcome had been used.
Another challenge was the presence of too little tumour mate-
rial of the FFPE primary melanoma, which occurred mainly in
thin melanomas (i.e. T1). Furthermore, the inclusion of T1
melanomas without SLN metastasis may have resulted in a
higher NPV. On the other hand, the percentage of T1 melano-
mas was significantly higher in the development cohort
(n = 192, 25%), of which six patients had a positive SLNB.
Moreover, NPV was high in both the development and valida-
tion cohorts (96% and 905%, respectively).29 Because the
algorithm has been bridged to a different platform (Quantstu-
dioDx), this study does not directly validate the development
platform (Fluidigm). To validate the CP-GEP algorithm, both
discovery and bridging have been done in a stringent docu-
ment-controlled product development environment and all
acceptance criteria, coefficients and the cut-off value were pre-
defined. To demonstrate the added value of using the CP-GEP
model in clinical practice, more validation data is required.
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In conclusion, the CP-GEP model includes two clinicopatho-
logical features (i.e. age and Breslow thickness) and can be
applied in any pathology laboratory with minimal processing
of the FFPE primary melanoma tissue (without the need for
macrodissection). It is a noninvasive and validated tool that is
able to identify patients with primary cutaneous melanoma
(T1–T3) at low risk for nodal metastasis. The CP-GEP model
is a promising tool for patient care with a low implementation
threshold, which may reduce the number of SLN-negative
procedures, and can guide doctors and patients in their clinical
decision-making for SLNB.
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